Description
Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research. It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells. By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise- Describes the different mechanisms of resistance; cooperation in net resistance to antileukemic drugs- Provides hallmark information about cell regulation pathways in drug resistance development- Brings information about causes of drug resistance in leukemia and hematologic malignancies including lymphoma and myeloma
Table of Contents
1. Drug classification for treatment Hematological Malignancies2. Reduce drug uptake in development of resistance3. The Role of Enhanced Drug Efflux in Drug Resistance4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy7. Altered cell cycle regulation8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor9. Immune system in resistance prediction10. Mechanisms of resistance of antibody-drug conjugates – obstacles to overcome11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
